Krishna Institute of Medical Sciences liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

4.34×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.76×	0.76×	0.83×	1.31×	1.61×
0.68×	0.68×	0.76×	1.20×	1.47×
70.5	70.5	78.0	130	129
−302	−302	−139	141	181

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

KIMS₹702.50

Krishna Institute of Medical Sciences Ltd.

· Pharma & Health

₹ CrorePeersAPOLLOHOSP MAXHEALTH FORTIS JUBLPHARMA INDGN ONESOURCE PFIZER POLYMEDMcap ₹28,100 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	4.34
Current Ratio	1.61	1.31	0.83	0.76	0.76
Quick Ratio	1.47	1.20	0.76	0.68	0.68
Cash, Equiv & ST Investments	129.5	129.9	78.0	70.5	70.5
Working Capital	181.2	140.7	-138.9	-301.5	-301.5

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.